Placebo-Controlled, Parallel-Group Study of SJP-0008 in Participants with Central Retinal Artery Occlusion

INTERVENTION: Administration of SJP‐0008 or Placebo, and blood collection CONDITION: Central Retinal Artery Occlusion PRIMARY OUTCOME: Efficacy SECONDARY OUTCOME: Efficacy and safety INCLUSION CRITERIA: ‐ Japanese Outpatients aged over 20 years at the time of signing informed consent (any gender) ‐ Patient with non‐arteritic Central Retinal Artery Occlusion ‐ Investigational Product will be administered within 3 to 48 hours after the onset of Central Retinal Artery Occlusion ‐ BCVA of the target eye is better than Hand Motion and worse than logMAR 1.0 (equivalent to decimal visual acuity of less than 0.1) ‐ Other protocol‐defined inclusion criteria may apply